The many neuroprogressive actions of tryptophan catabolites (TRYCATs) that may be associated with the pathophysiology of neuro-immune disorders

Current Pharmaceutical Design

Volumn 22, Issue 8, 2016, Pages 963-977

  Morris, Gerwyn ^a   Carvalho, André F ^b   Anderson, George ^c   Galecki, Piotr ^d   Maes, Michael ^e,f,g  

^a Tir Na Nog   (United Kingdom)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^c CRC Scotland and London   (United Kingdom)

^d UNIVERSITY OF LODZ   (Poland)

^e DEAKIN UNIVERSITY   (Australia)

^f STATE UNIVERSITY OF LONDRINA   (Brazil)

^g CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Chronic fatigue; Immune; Inflammation; Leaky gut; Oxidative and nitrosative stress; Schizophrenia

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AROMATIC HYDROCARBON RECEPTOR; BUNGAROTOXIN RECEPTOR; CYTOKINE; DOPAMINE; GLUTAMIC ACID; INDOLEAMINE 2,3 DIOXYGENASE; KAINIC ACID RECEPTOR; KYNURENIC ACID; QUINOLINIC ACID; TRYPTOPHAN; NEUROTOXIN;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BIOCHEMISTRY; BLOOD BRAIN BARRIER; CELL COMMUNICATION; CHRONIC FATIGUE SYNDROME; ENZYME ACTIVATION; FATIGUE; GLIA; HUMAN; INSULIN RESISTANCE; MAJOR DEPRESSION; METABOLIC SYNDROME X; METABOLITE; MITOCHONDRION; NERVE CELL; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NITROSATIVE STRESS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCHIZOPHRENIA; ANIMAL; DRUG EFFECTS; IMMUNOMODULATION; IMMUNOPATHOLOGY;

ANIMALS; HUMANS; IMMUNE SYSTEM DISEASES; NEUROIMMUNOMODULATION; NEUROTOXINS; TRYPTOPHAN;

EID: 84960192232     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151215102420     Document Type: Article

References (283)

1. Murakami Y, Hoshi M, Imamura Y, Arioka Y, Yamamoto Y, Saito K. Remarkable role of indoleamine 2, 3-dioxygenase and tryptophan metabolites in infectious diseases: Potential role in macrophagemediated inflammatory diseases. Mediat Inflamm 2013; 2013: 1-9.
2. Oxenkrug G. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann N Y Acad Sci 2010; 1199: 1-14.
3. Anderson G, Maes M. Redox regulation and the autistic spectrum: Role of tryptophan Catabolites, Immuno-inflammation, Autoimmunity and the amygdala. Curr Neuropharmacol 2014; 12: 148-67.
4. Wang Q, Liu D, Song P, Zou, MH. Tryptophan-kynurenine pathway is dysregulated in inflammation and immune activation. Front Biosci (Landmark Ed) 2015; 20: 1116-43.
5. Maes M, Leonard B, Myint A, Kubera M, Verkerk R. The new '5-HT' hypothesis of depression: Cell-mediated immune activation induces indoleamine 2, 3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 2011; 35: 702-21.
6. Anderson G, Berk M, Maes M. Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome. Acta Psychiatr Scand 2013; 129: 83-97.
7. Maes M, Mihaylova I, Ruyter M, Kubera M, Bosmans E. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression-and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 2007; 28: 826-31.
8. Savitz J, Drevets W, Wurfel B, et al. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav Immun 2015; 46: 55-9.
9. Savitz J, Drevets W, Smith C, et al. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacol 2014; 40: 463-71.
10. Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 2012; 196: 243-9.
11. Oxenkrug G. Insulin Resistance and Dysregulation of Tryptophan-Kynurenine and Kynurenine-Nicotinamide adenine dinucleotide metabolic pathways. Mol Neurobiol 2013; 48: 294-301.
12. Schefold J, Zeden J, Fotopoulou C, et al. Increased indoleamine 2, 3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant 2009; 24: 1901-8.
13. Mangge H, Summers K, Meinitzer A, et al. Obesity-related dysregulation of the Tryptophan-Kynurenine metabolism: Role of age and parameters of the metabolic syndrome. Obesity 2013; 22: 195-201.
14. Oxenkrug G, Turski W, Zgrajka W, Weinstock J, Summergrad P. Tryptophan-Kynurenine Metabolism and Insulin Resistance in Hepatitis C Patients. Hepat Res Treat 2013; 2013: 1-4.
15. Oxenkrug G. Increased plasma levels of xanthurenic and kynurenic acids in type 2 diabetes. Mol Neurobiol 2015; 52: 805-10.
16. Nemeth H, Toldi J, Vecsei L. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J Neural Transm Suppl 2006; 2006: 285-304.
17. Vecsei L, Schwab F. Kynurenine and its metabolites in nervous system diseases. Orv Hetil 1992; 133: 1803-7.
18. Vecsei L, Beal MF. Huntington's disease, behavioral disturbances, and kynurenines: preclinical findings and therapeutic perspectives. Biol Psychiatry 1996; 39: 1061-3.
19. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. J Neurol Sci 2005; 239: 31-5.
20. Rakoczi K, Klivenyi P, Vecsei L. Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings. Ideggyogy Sz 2009; 62: 25-34.
21. Kincses ZT, Vecsei L. Pharmacological therapy in Parkinson's disease: focus on neuroprotection. CNS Neurosci Ther 2010; 17: 345-67.
22. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in multiple sclerosis. Acta Neurol Scand 2005; 112: 93-6.
23. Rajda C, Bergquist J, Vecsei L. Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis. J Neural Transm Suppl 2007; 72: 323-9.
24. Mo X, Pi L, Yang J, Xiang Z, Tang A. Serum indoleamine 2, 3-dioxygenase and kynurenine aminotransferase enzyme activity in patients with ischemic stroke. J Clin Neurosci 2014; 21: 482-6.
25. Maes M, Galecki P, Verkerk R, Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2, 3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett 2011; 32: 264-73.
26. Barry S, Clarke G, Scully P, Dinan TG. Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol 2009; 23: 287-94.
27. Maes M, Scharpé S, Meltzer HY, et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994; 54: 143-60.
28. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90.
29. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 2000; 107: 343-53.
30. Baran H, Jellinger K, Deecke L. Kynurenine metabolism in Alzheimer's disease. J Neural Transm 1999; 106: 165-81.
31. Morris G, Berk M, Galecki P, Walder K, Maes M. The neuroimmune pathophysiology of central and peripheral fatigue in systemic immune-inflammatory and neuro-immune diseases. Mol Neurobiol 2015 [Epub ahead of print].
32. Morris G, Berk M, Walder K, Maes M. Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Med 2015; 13: 28.
33. Chen Y, Guillemin G. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res 2009; 2: 1-19.
34. Miura H, Shirokawa T, Isobe K, Ozaki N. Shifting the balance of brain tryptophan metabolism elicited by isolation housing and systemic administration of lipopolysaccharide in mice. Stress 2009; 12: 206-14.
35. Morris G, Maes M. Increased nuclear factor-+B and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Hypotheses 2012; 79: 607-13.
36. Love A, Schwartz I, Petzke M. Induction of indoleamine 2, 3-dioxygenase by Borrelia urgdorferi in human immune cells correlates with pathogenic potential. J Leukoc Biol 2014; 97: 379-90.
37. Jenabian M, El-Far M, Vyboh K, et al. Immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection. J Infect Dis 2015; 212: 355-66.
38. Beutelspacher S, Tan P, McClure M, Larkin D, Lechler R, George A. Expression of indoleamine 2, 3-Dioxygenase (IDO) by endothelial cells: Implications for the control of alloresponses. Am J Transplant 2006, 6: 1320-30.
39. Liu W, Lin YH, Xiao H, et al. Epstein-Barr virus infection induces indoleamine 2, 3-dioxygenase expression in human monocytederived macrophages through P38/mitogen-activated protein kinase and NF-B pathways: Impairment in T Cell Functions. J Virol 2014; 88: 6660-71.
40. Barth H, Raghuraman S. Persistent infectious diseases say-IDO. Role of indoleamine-2, 3-dioxygenase in disease pathogenesis and implications for therapy. Crit Rev Microbiol 2014, 40: 360-8.
41. Yamamoto T, Azechi H, Board M. Essential role of excessive tryptophan and its neurometabolites in fatigue. Can J Neurol Sci 2012, 39: 40-7.
42. Yamashita M, Yamamoto T. Tryptophan and kynurenic acid may produce an amplified effect in central fatigue induced by chronic sleep disorder. Int J Tryptophan Res 2014; 7: 9-14.
43. Kim S, Miller B, Stefanek M, Miller A. Inflammation-induced activation of the indoleamine 2, 3-dioxygenase pathway: Relevance to cancer-related fatigue. Cancer 2015; 121: 2129-36.
44. Morris G, Berk M. The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Medicine 2015; 13: 68.
45. Cunningham C. Microglia and neurodegeneration: The role of systemic inflammation. Glia 2012; 61: 71-90.
46. Polyzos K, Ketelhuth D. The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease. Hämostaseologie 2015; 35: 128-36.
47. Schwarcz R. Manipulation of brain kynurenines: Glial targets, Neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002; 303: 1-10.
48. Kwidzinski E, Bunse J, Aktas O, et al. Indolamine 2, 3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J 2005; 19: 1347-9.
49. Guillemin G, Kerr SJ, Smythe GA, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 2001; 78: 842-53.
50. Pemberton L, Kerr S, Smythe G, Brew B. Quinolinic Acid Production by Macrophages Stimulated with IFN-α, TNF-β, and IFN-γ. J Interferon Cytokine Res 1997; 17: 589-95.
51. Connor T, Starr N, O'Sullivan J, Harkin A. Induction of indolamine 2, 3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: A role for IFN-γ?. Neurosci Lett 2008; 441: 29-34.
52. Wirthgen E, Tuchscherer M, Otten W, et al. Activation of indoleamine 2, 3-dioxygenase by LPS in a porcine model. Innate Imm 2013; 20: 30-9.
53. Wang Y, Lawson M, Dantzer R, Kelley K. LPS-induced indoleamine 2, 3-dioxygenase is regulated in an interferon-γ-independent manner by a JNK signaling pathway in primary murine microglia. Brain Behav Immun 2010, 24: 201-9.
54. von Bergwelt-Baildon M. CD25 and indoleamine 2, 3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumorassociated dendritic cells in vivo: Additional mechanisms of T-cell inhibition. Blood 2006; 108: 228-37.
55. Schroecksnadel S, Jenny M, Kurz K, et al. LPS-induced NF-B expression in THP-1Blue cells correlates with neopterin production and activity of indoleamine 2, 3-dioxygenase. Biochem Biophys Res Commun 2010, 399: 642-6.
56. Ogasawara N, Oguro T, Sakabe T, et al. Hemoglobin induces the expression of indoleamine 2, 3-dioxygenase in dendritic cells through the activation of PI3K, PKC, and NF-+B and the generation of reactive oxygen species. J Cell Biochem 2009, 108: 716-25.
57. Ball H, Yuasa H, Austin C, Weiser S, Hunt N. Indoleamine 2, 3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol 2009, 41: 467-71.
58. Austin CJ, Rendina LM. Targeting key dioxygenases in tryptophankynurenine metabolism for immunomodulation and cancer chemotherapy. Drug Discov Today 2015; 20: 609-17.
59. Sedlmayr P, Blaschitz A, Stocker R. The role of placental tryptophan catabolism. Front Immunol 2014; 5: 230.
60. Platten M, Wick W, Van den Eynde B. Tryptophan catabolism in cancer: Beyond IDO and tryptophan depletion. Cancer Res 2012; 72: 5435-40.
61. Schwarcz R, Bruno J, Muchowski P, Wu H. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13: 465-77.
62. Wu W, Nicolazzo J, Wen L, et al. Expression of tryptophan 2, 3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's Disease brain. PLoS One 2013; 8: e59749.
63. Li JS, Han Q, Fang J, Rizzi M, James A, Li J. Biochemical mechanisms leading to tryptophan 2, 3-dioxygenase activation. Arch Insect Biochem Physiol 2007, 64: 74-87.
64. Kanai M. Implication of Tryptophan 2, 3-Dioxygenase and its novel variants in the hippocampus and cerebellum during the developing and adult brain. Int J Tryptophan Res 2010; 3: 141-9.
65. Campbell B, Charych E, Lee A, Möller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci 2014; 8: 12.
66. Reyes Ocampo J, Lugo Huitran R, Gonza¡lez-Esquivel D, et al. Kynurenines with neuroactive and redox properties: Relevance to aging and brain diseases. Oxid Med Cell Longev 2014, 2014: 646909.
67. Gal EM, Sherman AD. Synthesis and metabolism of l-kynurenine in rat brain. J Neurochem 1978; 30: 607-13.
68. Schuck PF, Tonin A, da Costa Ferreira G, et al. Kynurenines impair energy metabolism in rat cerebral cortex. Cell Mol Neurobiol 2007; 27: 147-60.
69. Gaubert S, Bouchaut M, Brumas V, Berthon G. Copper-Ligand interactions and the physiological free radical processes. Part 3. Influence of histidine, salicylic acid and anthranilic acid on copperdriven Fenton chemistry in vitro. Free Radic Res 2000; 32: 451-61.
70. Miche H, Brumas V, Berthon G. Copper (II) interactions with nonsteroidal antiinflammatory agents. II. Anthranilic acid as a potential. OH-inactivating ligand. J Inorg Biochem 1997; 68: 27-38.
71. Bender DA, McCreanor GM. The preferred route of kynurenine metabolism in the rat. Biochim Biophys Acta 1982; 717: 56-60.
72. Amaral M, Levy C, Heyes D, et al. Structural basis of kynurenine 3-monooxygenase inhibition. Nature 2013, 496: 382-5.
73. Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: A novel target for cognitive enhancement in schizophrenia. Schizophr Bull 2010; 36: 211-8.
74. Ishii T, Iwahashi H, Sugata R, Kido R. Formation of hydroxanthommatin-derived radical in the oxidation of 3-hydroxykynurenine. Arch Biochem Biophys 1992; 294: 616-22.
75. Okuda S, Nishiyama N, Saito H, Katsuki H. Hydrogen peroxidemediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc Natl Acad Sci USA 1996; 93: 12553-8.
76. Vazquez S, Garner B, Sheil MM, Truscott RJ. Characterisation of the major autoxidation products of 3-hydroxykynurenine under physiological conditions. Free Radic Res 2000; 32: 11-23.
77. Pinelli A, Ossi C, Colombo R, Tofanetti O, Spazzi L. Experimental convulsions in rats induced by intraventricular administration of kynurenine and structurally related compounds. Neuropharmacology1984; 23: 333-7.
78. Nakagami Y, Saito H, Katsuki H. 3-Hydroxykynurenine toxicity on the rat striatum in vivo. Jpn J Pharmacol 1996; 71: 183-6.
79. Mizdrak J, Hains PG, Truscott RJ, Jamie JF, Davies MJ. Tryptophan-derived ultraviolet filter compounds covalently bound to lens proteins are photosensitizers of oxidative damage. Free Radic Biol Med 2008; 44: 1108-19.
80. Leipnitz G, Schumacher C, Dalcin K, et al. In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain. Neurochem Int 2007; 50: 83-94.
81. Colin-Gonzalez AL, Maldonado PD, Santamaria A. 3-Hydroxykynurenine: An intriguing molecule exerting dual actions in the central nervous system. Neurotoxicol 2013; 34: 189-204.
82. Dykens JA, Sullivan SG, Stern A. Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinate. Biochem Pharmacol 1987; 36: 211-7.
83. Fazio F, Lionetto L, Molinaro G, et al. Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. Mol Pharmacol 2012; 81: 643-56.
84. Lowe MM, Mold J, Kanwar B, et al. Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production. PLoS One 2014; 9: e87877.
85. Morita T, Saito K, Takemura M, et al. 3-Hydroxyanthranilic acid, an l-tryptophan metabolite, induces apoptosis in monocyte-derived cells stimulated by interferon-gamma. Ann Clin Biochem 2001; 38: 242-51.
86. Quagliariello E, Papa S, Saccone C, Alifano A. Effect of 3-hydroxyanthranilic acid on the mitochondrial respiratory system. Biochem J 1964; 91: 137-46.
87. Fallarino F, Mold J, Kanwar B, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002; 9: 1069-77.
88. Murakami K, Ito M, Yoshino M. Xanthurenic acid inhibits metal ion-induced lipid peroxidation and protects NADP-isocitrate dehydrogenase from oxidative inactivation. J Nutr Sci Vitaminol 2001; 47: 306-10.
89. Murakami K, Haneda M, Qiao S, Naruse M, Yoshino M. Prooxidant action of rosmarinic acid: Transition metal-dependent generation of reactive oxygen species. Toxicol In Vitro 2007; 21: 613-7.
90. Bosco MC, Rapisarda A, Massazza S, Melillo G, Young H, Varesio L. The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1+ and-1+ in macrophages. J Immunol 2000; 164: 3283-91.
91. Jhamandas K, Boegman RJ, Beninger RJ, Bialik M. Quinolinateinduced cortical cholinergic damage: Modulation by tryptophan metabolites. Brain Res 1990; 529: 185-91.
92. Vrooman L, Jhamandas K, Boegman RJ, Beninger RJ. Picolinic acid modulates kainic acid-evoked glutamate release from the striatum in vitro. Brain Res 1993; 627: 193-8.
93. Prado De Carvalho L, Bochet P, Rossier J. The endogenous agonist quinolic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int 1996; 28: 445-52.
94. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992; 258: 597-603.
95. Foster A. On the excitotoxic properties of quinolinic acid, 2, 3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacol 1983, 22: 1331-42.
96. Tavares R, Tasca C, Santos C, et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 2002, 40: 621-7.
97. Tavares R, Tasca C, Santos C, Wajner M, Souza D, Dutra-Filho C. Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain. NeuroReport 2000, 11: 249-54.
98. Baverel G, Martin G, Michoudet C. Glutamine synthesis from aspartate in guinea-pig renal cortex. Biochem J 1990; 268: 437-42.
99. Ting K, Brew B, Guillemin G. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflamm 2009; 6: 36.
100. Bordelon Y, Chesselet M, Nelson D, Welsh F, Erecinska, M. Energetic dysfunction in quinolinic acid-lesioned rat striatum. J Neurochem 1997; 69: 1629-39.
101. Ribeiro C, Grando V, Dutra Filho C, Wannmacher C, Wajner M. Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats. J Neurochem 2006; 99: 1531-42.
102. Naoi M, Ishiki R, Nomura Y, Hasegawa S, Nagatsu T. Quinolinic acid: an endogenous inhibitor specific for type B monoamine oxidase in human brain synaptosomes. Neurosci Lett 1987; 74: 232-36.
103. Bordelon Y, Chesselet M, Erecinska M, Silver I. Effects of intrastriatal injection of quinolinic acid on electrical activity and extracellular ion concentrations in rat striatum in vivo. Neuroscience 1998; 83: 459-69.
104. Cabrera J, Reiter R, Tan D, et al. Melatonin reduces oxidative neurotoxicity due to quinolinic acid. Neuropharmacology 2000; 39: 507-14.
105. Ganzella M, Jardim F, Boeck C, Vendite D. Time course of oxidative events in the hippocampus following intracerebroventricular infusion of quinolinic acid in mice. Neurosci Res 2006; 55: 397-402.
106. Braidy N, Grant R, Adams S, Guillemin G. Neuroprotective effects of naturally occurring Braidy polyphenols on quinolinic acidinduced excitotoxicity in human neurons. FEBS J 2009; 277: 368-82.
107. Perez-De La Cruz V, et al. Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: Protective role of iron porphyrinate 5, 10, 15, 20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III). Neuroscience 2005; 135: 463-74.
108. Leipnitz G, Schumacher C, Scussiato K, et al. Quinolinic acid reduces the antioxidant defenses in cerebral cortex of young rats. Int J Dev Neurosci 2005, 23: 695-701.
109. Iwahashi H, Kawamori H, Fukushima K. Quinolinic acid, α-picolinic acid, fusaric acid, and 2, 6-pyridinedicarboxylic acid enhance the Fenton reaction in phosphate buffer. Chemico-Biol Interactions 1999, 118: 201-15.
110. Goda K, Kishimoto R, Shimizu S, Hamane Y, Ueda M. Quinolinic acid and active oxygens. Possible contribution of active Oxygens during cell death in the brain. Adv Exp Med Biol 1996; 398: 247-54.
111. Carmona-Ramírez I, Santamara A, Toban-Velasco J, et al. Curcumin restores Nrf2 levels and prevents quinolinic acid-induced neurotoxicity. J Nutr Biochem 2013; 24: 14-24.
112. Rodríguez-Martínez E, Camacho A, Maldonado P, et al. Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res 2000; 858: 436-9.
113. Noack H, Lindenau J, Rothe F, Asayama K, Wolf G. Differential expression of superoxide dismutase isoforms in neuronal and glial compartments in the course of excitotoxically mediated neurodegeneration: Relation to oxidative and nitrergic stress. Glia 1998; 23: 285-97.
114. Hayashi M, Luo Y, Laning J, Strieter R, Dorf M. Production and function of monocyte chemoattractant protein-1 and other Îα-chemokines in murine glial cells. J Neuroimmunol 1995, 60: 143-50.
115. Guillemin G, Croitoru-Lamoury J, Dormont D, Armati P, Brew B. Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia 2003, 41: 371-81.
116. da Fonseca A, Matias D, Garcia C, et al. The impact of microglial activation on blood-brain barrier in brain diseases. Front Cell Neurosci 2014, 8: 362.
117. Willis C. Glia-Induced Reversible Disruption of Blood-Brain Barrier Integrity and Neuropathological Response of the Neurovascular Unit. Toxicol Pathol 2010, 39: 172-85.
118. Cabezas R, Ãfavila M, Gonzalez J, et al. Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. Front Cell Neurosci 2014; 8: 211.
119. Kincses Z, Toldi J, Vecsei L. Kynurenines, neurodegeneration and Alzheimer's disease. J Cell Mol Med 2010; 14: 2045-54.
120. Kells A, Henry R, Connor B. AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment. Gene Therapy 2008; 15: 966-77.
121. Pierozan P, Zamoner A, Krombauer Soska  et al. Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats. Exper Neurol 2010; 224: 188-96.
122. Rahman A, Ting K, Cullen K, Braidy N, Brew B, Guillemin G. The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons. PLoS One 2009; 4: p. e6344.
123. Portera-Cailliau C, Price D, Martin L. Non-NMDA and NMDA receptor-mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: Further evidence for an apoptosis-necrosis continuum. J Comp Neurol 1997; 378: 88-104.
124. Jeon B, Kholodilov N, Oo T, et al. Activation of caspase-3 in developmental models of programmed cell death in neurons of the substantia nigra. J Neurochem 1999; 73: 322-33.
125. Guillemin GJ, Wang L, Brew BJ. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflamm 2005; 2: 16.
126. Perez-Navarro E, Gavalda N, Gratacos E, Alberch J. Brain-derived neurotrophic factor prevents changes in Bcl-2 family members and caspase-3 activation induced by excitotoxicity in the striatum. J Neurochem 2005; 92: 678-91.
127. Wang YR, Qin S, Han R, et al. Cathepsin L plays a role in quinolinic acid-induced NF-+b activation and excitotoxicity in rat striatal neurons. PLoS One 2013; 8: e75702.
128. Perkins MN, Stone TW. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 1982; 247: 184-7.
129. Grilli M, Raiteri L, Patti L, et al. Modulation of the function of presynaptic alpha7 and non-alpha7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brain. Br J Pharmacol 2006; 149: 724-32.
130. Wu HQ, Pereira EF, Bruno JP, Pellicciari R, Albuquerque EX, Schwarcz R. The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci 2010; 40: 204-10.
131. Lopes C, Pereira E, Wu H, et al. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7 nicotinic receptors. J Pharmacol Exp Ther 2007; 322: 48-58.
132. DiNatale BC, Murray I, Schroeder J, et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci 2010; 115: 89-97.
133. Wang J. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 2006; 281: 22021-8.
134. Hardeland R, Zsizsik BK, Poeggeler B, Fuhrberg B, Holst S, Coto-Montes A. Indole-3-pyruvic and-propionic acids, kynurenic acid, and related metabolites as luminophores and free-radical scavengers. Adv Exp Med Biol 1999; 467: 389-95.
135. Lugo-Huitron R, Blanco-Ayala T, Ugalde-MuÃtiz P, et al. On the antioxidant properties of kynurenic acid: Free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol 2011; 33: 538-47.
136. Smythe GA, Poljak A, Bustamante S, et al. ECNI GC-MS analysis of picolinic and quinolinic acids and their amides in human plasma, CSF, brain tissue. Adv Exp Med Biol 2003; 527: 705-12.
137. Guidetti P, Eastman CL, Schwarcz R. Metabolism of [5-3H] kynurenine in the rat brain in vivo: evidence for the existence of a functional kynurenine pathway. J Neurochem 1995; 65: 2621-32.
138. Yu P, Di Prospero N, Sapko M, et al. Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice. Mol Cell Biol 2004; 24: 6919-30.
139. Carpenedo R, Pittaluga A, Cozzi A, et al. Presynaptic kynurenatesensitive receptors inhibit glutamate release. Eur J Neurosci 2001; 13: 2141-7.
140. Rassoulpour A, Wu HQ, Ferré S, Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem 2005; 93: 762-5.
141. Amori L, Wu HQ, Marinozzi M, Pellicciari R, Guidetti P, Schwarcz R. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience 2009; 159: 196-203.
142. Zmarowski A, Wu H, Brooks J, et al. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci 2009; 29: 529-38.
143. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009; 89: 73-120.
144. Guidetti P, Hoffman GE, Melendez-Ferro M, Albuquerque EX, Schwarcz R. Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia 2007; 55: 78-92.
145. Han Q, Cai T, Tagle DA, Li J. Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci 2010; 67: 353-68.
146. Wonodi I. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 2011; 68: 665-74.
147. Wonodi I, McMahon R, Krishna N, et al. Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia. Schizophr Res 2014; 160: 80-7.
148. Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 2004; 56: 255-60.
149. Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr. Bull 2007; 33: 797-804.
150. Chess AC, Landers AM, Bucci DJ. L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cuespecific fear conditioning. Behav Brain Res 2009; 201: 325-31.
151. Olsson SK, Andersson A, Linderholm K, et al. Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int J Neuropsychopharmacol 2009; 12: 501-12.
152. Kegel ME, Bhat M, Skogh E, et al. Imbalanced kynurenine pathway in schizophrenia. Int J Tryptophan Res 2014 16; 7: 15-22.
153. Schwieler L, Larsson MK, Skogh E, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenine pathway. J Psychiatry Neurosci 2015; 40: 126-33.
154. Linderholm KR, Skogh E, Olsson S, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2012; 38: 426-32.
155. Nilsson LK, Linderholm K, Engberg G, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 2005; 80: 315-22.
156. Erhardt S, Blennow K, Nordin C, et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001; 313: 96-8.
157. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50: 521-30.
158. Ceresoli-Borroni G, Rassoulpour A, Wu HQ, Guidetti P, Schwarcz R. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm 2006; 113: 1355-65.
159. Sathyasaikumar KV, Stachowski E, Wonodi I, et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 2011; 37: 1147-56.
160. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009; 50: 1801-7.
161. van Berckel BN, Bossong M, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008; 64: 820-2.
162. Maes M, Meltzer H, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994; 89: 346-51.
163. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008; 63: 801-8.
164. Sasayama D, Hattori K, Wakabayashi C, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 2013; 47: 401-6.
165. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2, 3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 2004; 15: 618-29.
166. Miller CL, Murakami P, Ruczinski I, et al. Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. Schizophr Res 2009; 113: 259-67.
167. Söderlund J, Schrader J, Nordin C, et al. Activation of brain interleukin-1+ in schizophrenia. Mol Psychiatry 2009; 14: 1069-71.
168. Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature 2009; 460: 744-7.
169. Müller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 2006; 10: 131-48.
170. Holtze M, Saetre P, Erhardt S, et al. Kynurenine 3-monooxygenase (KMO) polymorphisms in schizophrenia: An association study. Schizophr Res 2011, 127: 270-2.
171. Lavebratt C, Olsson S, Backlund L, et al. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol Psychiatry 2013; 19: 334-41.
172. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006; 1073-4: 25-37.
173. Guidetti P, Reddy PH, Tagle DA, Schwarcz R. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model. Neurosci Lett 2000; 283: 233-5.
174. Giorgini F, Moller T, Kwan W, et al. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J Biol Chem 2008; 283: 7390-400.
175. Campesan S, Green E, Breda C, et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol 2011; 21: 961-6.
176. Erhardt S, Engberg G. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand 2002; 175: 45-53.
177. Schubert KO, Föcking M, Cotter DR. Proteomic pathway analysis of the hippocampus in schizophrenia and bipolar affective disorder implicates 14-3-3 signaling, aryl hydrocarbon receptor signaling, and glucose metabolism: Potential roles in GABAergic interneuron pathology. Schizophr Res 2015; 167(1-3): 64-72.
178. Tanida T, Tasaka K, Akahoshi E, et al. Fetal exposure to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin transactivates aryl hydrocarbon receptor-responsive element III in the tyrosine hydroxylase immunoreactive neurons of the mouse midbrain. J Appl Toxicol 2014; 34(2): 117-26.
179. Anderson G. Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Med Hypotheses 2011; 76: 54-60.
180. Anderson G, Maes M. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 5-19.
181. Schwarz MJ, Guillemin GJ, Teipel SJ, Buerger K, Hampel H. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls. Eur Arch Psychiatr Clin Neurosci 2013; 263: 345-52.
182. Tapiola T, Lehtovirta M, Pirttila T, Alafuzoff I, Riekkinen P, Soininen H. Increased aspartate aminotransferase activity in cerebrospinal fluid and Alzheimer's disease. Lancet 1998; 352: 287.
183. Hartai Z, Juha¡sz A, Rimanaczy Ã, et al. Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem Int 2007; 50: 308-13.
184. Heyes MP, Saito K, Crowley J, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and noninflammatory neurological disease. Brain 1992; 115: 1249-73.
185. Sofic E, Halket J, Przyborowska A, et al. Brain quinolinic acid in Alzheimer's dementia. Eur Arch Psychiatry Neurol Sci 1989; 239: 177-9.
186. Guillemin GJ, Smythe GA, Veas LA, Takikawa O, Brew BJ. A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport 2003; 14: 2311-15.
187. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. Indoleamine 2, 3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 2005; 31: 395-404.
188. Anderson G, Ojala J. Alzheimer's and seizures: interleukin-18, indoleamine 2, 3-dioxygenase and quinolinic acid. Int J Tryptophan Res 2010; 3: 169-73.
189. Bonda DJ, Mailankot M, Stone JG, et al. Indoleamine 2, 3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep 2010; 15: 161-8.
190. Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One 2009; 4: e6344.
191. Cermak N, Yamamoto T, Meeusen R, Burke LM, Stear SJ, Castell LM. A-Z of nutritional supplements: dietary supplements, sports nutrition foodsergogenic aids for health and performance: part 38. Br J Sports Med 2012; 46: 1027-8.
192. Yamamoto T, Castell L, Botella J, et al. Changes in the albumin binding of tryptophan during postoperative recovery: a possible link with central fatigue? Brain Res Bull 1997; 43: 43-6.
193. Acworth I, Nicholass J, Morgan B, Newsholme EA. Effect of sustained exercise on concentrations of plasma aromatic and branchedchain amino acids and brain amines. Biochem Biophys Res Commun 1986; 137: 149-153.
194. Melancon M, Lorrain D, Dionne I. Exercise Increases Tryptophan Availability to the Brain in Older Men Age 57 70 Years. Med Sci Sports Exerc 2012; 44: 881-7.
195. Newsholme EA, Blomstrand E. Branched-chain amino acids and central fatigue. J Nutr 2006; 136: 274S-6S.
196. Fernstrom JD, Fernstrom MH. Exercise, serum free tryptophan, and central fatigue. J Nutr 2006; 136: 553S-9S.
197. Soares D, Coimbra C, Marubayashi U. Tryptophan-induced central fatigue in exercising rats is related to serotonin content in preoptic area. Neurosci Lett 2007; 415: 274-8.
198. Leite L, Rodrigues A, Soaers D, Marubayashi U, Coimbra C. Central Fatigue Induced by Losartan Involves Brain Serotonin and Dopamine Content. Med Sci Sports Exerc 2010; 42: 1469-76.
199. Xu C, Liu H, Wang J. Changes of 5-hydroxytryptamine and tryptophan hydroxylase expression in the ventral horn of spinal cord. Neurosci Bull 2008; 24: 29-33.
200. Cordeiro L, Guimara£es J, Wanner S, et al. Inhibition of tryptophan hydroxylase abolishes fatigue induced by central tryptophan in exercising rats. Scand J Med Sci Sports 2012; 24: 80-8.
201. Watson P, Shirreffs SM, Maughan RJ. Blood-brain barrier integrity may be threatened by exercise in a warm environment. Am J Physiol Regul Integ Comp Physiol 2005; 288: R1689-94.
202. Nierwinska K, Malecka E, Chalimoniuk M, Zebrowska A, Langfort J. Blood-brain barrier and exercise-a short review. J Hum Kinet 2008; 19: 83-92.
203. Ormstad H, Verkerk R, Amthor K, Sandvik L. Activation of the kynurenine pathway in the acute phase of stroke and its role in fatigue and depression following stroke. J Mol Neurosci 2014; 54: 181-7.
204. Blankfield A. Kynurenine pathway pathologies: do nicotinamide and other pathway co-factors have a therapeutic role in reduction of symptom severity, including chronic fatigue syndrome (CFS) and fibromyalgia (FM). Int J Tryptophan Res 2013; 6: 39-45.
205. Blankfield A. Kynurenine pathway hypothesis: the nature of the chronic fatigue syndrome (CFS) revisited. Int J Tryptophan Res 2011; 4 47-48.
206. Anderson G, Maes M. Redox Regulation and the Autistic Spectrum: Role of Tryptophan Catabolites, Immuno-inflammation, Autoimmunity and the Amygdala. Curr Neuropharmacol 2014; 12: 148-7.
207. Anderson G, Maes M, Berk M. Schizophrenia is primed for an increased expression of depression through activation of immunoinflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuro-Psychopharmacol Biol Psychiatry 2013; 42: 101-4.
208. Rattray B, Argus C, Martin K, Northey J, Driller M. Is it time to turn our attention toward central mechanisms for post-exertional recovery strategies and performance? Front Physiol 2015; 6: 79.
209. Coppola A, Wenner B, Ilkayeva O, et al. Branched-chain amino acids alter neurobehavioral function in rats. Am J Physiol Endocrinol Metab 2012; 304: E405-13.
210. Yamamoto T, Azechi H, Board M. Essential Role of Excessive Tryptophan and its Neurometabolites in Fatigue. Can J Neurol Sci 2012; 39: 40-7.
211. Maes M, Kubera M, Leunis JC, Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord 2012; 141: 55-62.
212. Maes M, Twisk FN, Kubera M, Ringel K, Leunis JC, Geffard M. Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome. J Affect Disord 2012; 136: 909-17.
213. Maes M, Leunis JC. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gramnegative bacteria. Neuro Endocrinol Lett 2008; 29: 902-10.
214. Lucas K, Morris G, Anderson G, Maes M. The toll-like receptor radical cycle pathway: a new drug target in immune-related chronic fatigue. CNS & Neurol Dis-Drug Targets 2015; 14: 838-54.
215. Lucas K, Maes M. Role of the toll like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol 2013; 48: 190-204.
216. Qin L, Wu X, Block M, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007; 55: 453-62.
217. Goehler LE, Lyte M, Gaykema RP. Infection-induced viscerosensory signals from the gut enhance anxiety: implications for psychoneuroimmunology. Brain Behav Immun 2007; 21: 721-6.
218. Morris G, Anderson G, Galecki P, Berk M, Maes M. A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior. BMC Med 2013; 11: 64.
219. Weber MD, Frank MG, Tracey KJ, Watkins LR, Maier SF. Stress induces the danger-associated molecular pattern HMGB-1 in the hippocampus of male Sprague Dawley rats: a priming stimulus of microglia and the NLRP3 inflammasome. J Neurosci 2015; 35: 316-24.
220. Sutinen EM, Pirttilä T, Anderson G, Salminen A, Ojala JO. Proinflammatory interleukin-18 increases Alzheimer's diseaseassociated amyloid-β production in human neuron-like cells. J Neuroinflamm 2012; 9: 199.
221. Haroon E, Anand R, Chen X, et al. Interferon-alpha-induced fatigue is associated with alterations in CNS glutamate metabolism as measured by magnetic resonance spectroscopy. Brain Beh Imm 2012; 26: S49-50.
222. Wang Z, Pekarskaya O, Bencheikh M, et al. Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. Virology 2003; 312: 60-73.
223. Ida T, Hara M, Nakamura Y, Kozaki S, Tsunoda S, Ihara H. Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci Lett 2008; 432: 232-6.
224. Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007; 85: 2059-70.
225. Howells F, Russell V. Glutamate-stimulated release of norepinephrine in hippocampal slices of animal models of attentiondeficit/hyperactivity disorder (spontaneously hypertensive rat) and depression/anxiety-like behaviours (Wistar-Kyoto rat). Brain Res 2008; 1200: 107-15.
226. Russell V, Allie S, Wiggins T. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hy peractivity disorder-the spontaneously hypertensive rat. Behav Brain Res 2000; 117: 69-74.
227. Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH 2nd. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 2008; 152: 785-97.
228. Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol 2012; 33: 315-27.
229. Morris G, Berk M, Walder K, Maes M. The putative role of viruses, bacteria, and chronic fungal biotoxin exposure in the genesis of intractable fatigue accompanied by cognitive and physical disability. Mol Neurobiol 2015; [Epub ahead of print].
230. Morris G, Anderson G, Galecki P, Berk M, Maes M. A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior. BMC Med 2013; 11: 64.
231. Agaugue S, Perrin-Cocon L, Coutant F, Andre P, Lotteau V. 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J Immunol 2006; 177: 2061-71.
232. Puccetti P, Fallarino F. Generation of T cell regulatory activity by plasmacytoid dendritic cells and tryptophan catabolism. Blood Cells Mol Dis 2008; 40: 101-5.
233. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 1219-26.
234. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008; 8: 74-80.
235. Terness P, Kallikourdis M, Betz AG, Rabinovich GA, Saito S, Clark DA. Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells. Am J Reprod Immunol 2007; 58: 238-54.
236. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008; 222: 206-21.
237. Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase and tumorinduced tolerance. J Clin Invest 2007; 117: 1147-54.
238. Terness P, Chuang JJ, Opelz G. The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol 2006; 27: 68-73.
239. Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor β-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176: 6752-61.
240. MacKenzie CR, Heseler K, Muller A, Daubener W. Role of indoleamine 2, 3-dioxygenase in antimicrobial defence and immunoregulation: tryptophan depletion versus production of toxic kynurenines. Curr Drug Metab 2007; 8: 237-44.
241. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 2002; 1: 609-20.
242. Molano A, Illarionov PA, Besra GS, Putterman C, Porcelli SA. Modulation of invariant natural killer T cell cytokine responses by indoleamine 2, 3-dioxygenase. Immunol Lett 2008; 117: 81-90.
243. Platten M. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005; 310: 850-5.
244. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002; 9: 1069-77.
245. Orabona C, Tomasello E, Fallarino F, et al. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 2006; 107: 2846-54.
246. Orabona C, Tomasello E, Fallarino F, et al. Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. Eur J Immunol 2005; 35: 3111-8.
247. Orabona C, Grohmann U. Indoleamine 2, 3-dioxygenase and regulatory function: tryptophan starvation and beyond. Methods Mol Biol 2011; 677: 269-80.
248. Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm 2012; 119: 197-209.
249. Kamal Bassal N, P Hughes B, Costabile M. Tryptophan metabolism-indoleamine 2, 3-dioxygenase-friend and Foe. J Metabol Metab 2012; 87: 119-26.
250. Mezrich J, Fechner J, Zhang X, Johnson B, Burlingham W, Bradfield C. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010; 185: 3190-8.
251. Yan Y, Zhang GX, Gran B, et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol 2010; 185: 5953-61.
252. Xu H, Zhang G, Ciric B, Rostami A. IDO: A double-edged sword for TH1/TH2 regulation. Immunol Lett 2008; 121: 1-6.
253. DiNatale B, Murray I, Schroeder J, et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci 2010; 115: 89-97.
254. Morris G, Maes M. Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med 2013; 11: 205.
255. Owe-Young R, Webster N, Mukhtar M, et al. Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance & neurotoxicity. J Neurochem 2008; 105: 1346-57.
256. Moreau M, Andrea C, Oâe M, et al. Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav Immun 2008; 22: 1087-95.
257. Macchiarulo A, Camaioni E, Nuti R, Pellicciari R. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2, 3-dioxygenase (IDO), a novel target in cancer disease. Amino Acids 2008; 37: 219-29.
258. Martín M, Macías M, León J, Escames G, Khaldy H, Acuña-Castroviejo D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002; 34: 348-57.
259. Anderson G, Maes M. TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's disease. CNS Neurol Disord Drug Targets 2014; 13: 137-49.
260. Anderson G. Melatonin and Cognitive Deficits in Bipolar Disorder and Mild Cognitive Impairment. Psychother Psychosom 2012; 81: 244.
261. Anderson G, Maes M. Melatoninergic Pathways in Alzheimer's Disease. In: Atta-Ur-Rahman, Ed. Frontiers in Clinical Drug Research-Alzheimer Disorder. UAE: Bentham Press e-books 2015; vol. 4: pp. 3-39.
262. Anderson G, Maes M. Redox regulation and the autistic spectrum: role of tryptophan catabolites, immuno-inflammation, autoimmunity and the amygdala. Curr Neuropharmacol 2014; 12: 148-67.
263. Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metabol Brain Dis 2012; 27: 113-9.
264. Calvo JR, González-Yanes C, Maldonado MD. The role of melatonin in the cells of the innate immunity: a review. J Pineal Res 2013; 55: 103-20.
265. Muxel SM, Pires-Lapa MA, Monteiro AW, et al. NF-kB Drives the Synthesis of Melatonin in RAW 264. 7 Macrophages by Inducing the Transcription of the Arylalkylamine-Nacetyltransferase (AANAT) Gene. PLoS One 2012; 7: e52010.
266. Trivedi PP, Jena GB. Melatonin reduces ulcerative colitisassociated local and systemic damage in mice: investigation on possible mechanisms. Dig Dis Sci 2013; 58: 3460-74.
267. Pontes GN, Cardoso EC, Carneiro-Sampaio MM, Markus RP. Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppresses nocturnal melatonin production. J Pineal Res 2007; 43: 365-71.
268. Markus RP, Cecon E, Pires-Lapa MA. Immune-pineal axis: nuclear factor +B (NF-kB) mediates the shift in the melatonin source from pinealocytes to immune competent cells. Int J Mol Sci 2013; 14: 10979-97.
269. Tan DX, Manchester LC, Liu X, Rosales-Corral SA, Acuna-Castroviejo D, Reiter RJ. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin's primary function and evolution in eukaryotes. J Pineal Res 2013; 54: 127-8.
270. Anderson G, Maes M. Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. CNS Neurol Disord Drug Targets 2014; 13: 817-27.
271. Lynch C, Adams S. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol 2014; 10: 723-6.
272. Zhang Y, Guo K, LeBlanc R, Loh D, Schwartz G, Yu Y. Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms. Diabetes 2007; 56: 1647-54.
273. Nakamura H, Jinzu H, Nagao K, Noguchi Y, Shimba N, Miyano H, Watanabe T, Iseki K. Plasma amino acid profiles are associated with insulin, C-peptide and adiponectin levels in type 2 diabetic patients. Nutr Diab 2014; 4: e133.
274. Kadota Y, Toyoda T, Kitaura Y, Adams S, Shimomura Y. Regulation of hepatic branched-chain β-ketoacid dehydrogenase complex in rats fed a high-fat diet. Obes Res Clin Practi 2013; 7: e439-e444.
275. Wikoff W, Anfora A, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 2009; 106: 3698-703.
276. Song I, Lee D, Shin M, et al. Pharmacogenetics meets metabolomics: discovery of tryptophan as a new endogenous OCT2 substrate related to metformin disposition. PLoS One 2012; 7: e36637.
277. Myint A, Kim Y, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: Evidence of impaired neuroprotection. J Affect Disord 2007; 98: 143-51.
278. Maes M, Galecki P, Verkerk R, Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2, 3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett 2011; 32: 264-73.
279. Winiewski J, Gaugaz F. Fast and sensitive total protein and peptide assays for proteomic analysis. Anal Chem 2015; 87: 4110-6.
280. Mailler N, Myint A, Schwarz M. Inflammation in schizophrenia. In: Donev R, Ed. Inflammation in neuropsychiatric disorders, 1st ed. Oxford: Academic Press 2012; pp. 49-51.
281. Schwarz M, Myint A, Mueller N. Cytokines-kynurenines interaction: Controversies and consequences in schizophrenia. Brain Behav Immun 2010; 24: S52.
282. Rajkowska G, Stockmeier C. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 2013; 14: 1225-36.
283. Kegel Bhat M, Skogh E, Samuelsson M, et al. Imbalanced kynurenine pathway in schizophrenia. IJTR 2014; 7: 15.